Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

Hims & Hers (NYSE: HIMS) has skyrocketed 120% in just a month! Is it the next big disruptor in healthcare, or is it ...

Shares of Hims & Hers (NYSE: HIMS) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the ...

Shares of Hims & Hers Health (HIMS) are down at the time of writing after Morgan Stanley, led by four-star analyst Craig Hettenbach, ...

Fintel reports that on February 18, 2025, Morgan Stanley downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from ...

It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.

Hims & Hers (HIMS) stock dips as Morgan Stanley downgrades the telehealth firm citing its recent rally in share price. Read more here.

BTIG analyst David Larsen maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of $85.00.

Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $36.43, ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...